Mind Medicine completes enrollment in study of lysergide D-tartrate for GAD

Mind Medicine announced that it has completed enrollment and dosing in Study MMED008, the Company’s Phase 2b study evaluating MM-120,lysergide D-tartrate, for the treatment of GAD. “Completion of enrollment of this study is a significant milestone for MindMed and moves us one step closer to our goal of transforming the treatment of GAD for the millions suffering from the disorder,” said Robert Barrow, Chief Executive Officer and Director of MindMed. “Thanks in large part to the enthusiasm we have seen regarding MM-120 among investigators and patients, as well as the strong execution of our team, we were able to enroll almost 200 participants in this trial in just over a year. We anticipate sharing topline results during the fourth quarter of this year.”